TY - JOUR
T1 - Retinal oximetry
T2 - Metabolic imaging for diseases of the retina and brain
AU - Stefánsson, Einar
AU - Olafsdottir, Olof Birna
AU - Eliasdottir, Thorunn S.
AU - Vehmeijer, Wouter
AU - Einarsdottir, Anna Bryndis
AU - Bek, Toke
AU - Torp, Thomas Lee
AU - Grauslund, Jakob
AU - Eysteinsson, Thor
AU - Karlsson, Robert Arnar
AU - Van Keer, Karel
AU - Stalmans, Ingeborg
AU - Vandewalle, Evelien
AU - Todorova, Margarita G.
AU - Hammer, Martin
AU - Garhöfer, Gerhard
AU - Schmetterer, Leopold
AU - Šín, Martin
AU - Hardarson, Sveinn Hakon
N1 - Publisher Copyright:
© 2019
PY - 2019/5
Y1 - 2019/5
N2 - Retinal oximetry imaging of retinal blood vessels measures oxygen saturation of hemoglobin. The imaging technology is non-invasive and reproducible with remarkably low variability on test-retest studies and in healthy cohorts. Pathophysiological principles and novel biomarkers in several retinal diseases have been discovered, as well as possible applications for systemic and brain disease. In diabetic retinopathy, retinal venous oxygen saturation is elevated and arteriovenous difference progressively reduced in advanced stages of retinopathy compared with healthy persons. This correlates with pathophysiology of diabetic retinopathy where hypoxia stimulates VEGF production. Laser treatment and vitrectomy both improve retinal oximetry values, which correlate with clinical outcome. The oximetry biomarker may allow automatic measurement of severity of diabetic retinopathy and predict its response to treatment. Central retinal vein occlusion is characterized by retinal hypoxia, which is evident in retinal oximetry. The retinal hypoxia seen on oximetry correlates with the extent of peripheral ischemia, visual acuity and thickness of macular edema. This biomarker may help diagnose and measure severity of vein occlusion and degree of retinal ischemia. Glaucomatous retinal atrophy is associated with reduced oxygen consumption resulting in reduced arteriovenous difference and higher retinal venous saturation. The oximetry findings correlate with worse visual field, thinner nerve fiber layer and smaller optic disc rim. This provides an objective biomarker for glaucomatous damage. In retinitis pigmentosa, an association exists between advanced atrophy, worse visual field and higher retinal venous oxygen saturation, lower arteriovenous difference. This biomarker may allow measurement of severity and progression of retinitis pigmentosa and other atrophic retinal diseases. Retinal oximetry offers visible light imaging of systemic and central nervous system vessels. It senses hypoxia in cardiac and pulmonary diseases. Oximetry biomarkers have been discovered in Alzheimer's disease and multiple sclerosis and oxygen levels in the retina correspond well with brain.
AB - Retinal oximetry imaging of retinal blood vessels measures oxygen saturation of hemoglobin. The imaging technology is non-invasive and reproducible with remarkably low variability on test-retest studies and in healthy cohorts. Pathophysiological principles and novel biomarkers in several retinal diseases have been discovered, as well as possible applications for systemic and brain disease. In diabetic retinopathy, retinal venous oxygen saturation is elevated and arteriovenous difference progressively reduced in advanced stages of retinopathy compared with healthy persons. This correlates with pathophysiology of diabetic retinopathy where hypoxia stimulates VEGF production. Laser treatment and vitrectomy both improve retinal oximetry values, which correlate with clinical outcome. The oximetry biomarker may allow automatic measurement of severity of diabetic retinopathy and predict its response to treatment. Central retinal vein occlusion is characterized by retinal hypoxia, which is evident in retinal oximetry. The retinal hypoxia seen on oximetry correlates with the extent of peripheral ischemia, visual acuity and thickness of macular edema. This biomarker may help diagnose and measure severity of vein occlusion and degree of retinal ischemia. Glaucomatous retinal atrophy is associated with reduced oxygen consumption resulting in reduced arteriovenous difference and higher retinal venous saturation. The oximetry findings correlate with worse visual field, thinner nerve fiber layer and smaller optic disc rim. This provides an objective biomarker for glaucomatous damage. In retinitis pigmentosa, an association exists between advanced atrophy, worse visual field and higher retinal venous oxygen saturation, lower arteriovenous difference. This biomarker may allow measurement of severity and progression of retinitis pigmentosa and other atrophic retinal diseases. Retinal oximetry offers visible light imaging of systemic and central nervous system vessels. It senses hypoxia in cardiac and pulmonary diseases. Oximetry biomarkers have been discovered in Alzheimer's disease and multiple sclerosis and oxygen levels in the retina correspond well with brain.
KW - Alzheimer's disease
KW - Biomarker
KW - Brain
KW - Cardiac output
KW - Central circulation
KW - Classification
KW - Diabetic retinopathy
KW - Eye
KW - Glaucoma
KW - Heart
KW - Multiple sclerosis
KW - Oxygen
KW - Progression of glaucoma
KW - Retina
KW - Retinal atrophy
KW - Retinal dystrophy
KW - Retinal oximetry
KW - Retinal vein occlusion, retinal ischemia
KW - Retinitis pigmentosa
UR - http://www.scopus.com/inward/record.url?scp=85064464140&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85064464140&partnerID=8YFLogxK
U2 - 10.1016/j.preteyeres.2019.04.001
DO - 10.1016/j.preteyeres.2019.04.001
M3 - Review article
C2 - 30999027
AN - SCOPUS:85064464140
SN - 1350-9462
VL - 70
SP - 1
EP - 22
JO - Progress in Retinal and Eye Research
JF - Progress in Retinal and Eye Research
ER -